Alterity Therapeutics to Present at the 34th Annual Roth Conference

MELBOURNE,Australia and SAN FRANCISCO,March 7,2022 -- Alterity Therapeutics(ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"),a biotechnology company dedicatedto developing disease modifying treatments for neurodegenerative diseases,today announcedthat David Stamler,M.D.,Chief Executive Officer will present a company update and participatein investormeetingsatthe34thAnnualRothConference.

The conference is taking place Monday,14 March and Tuesday,15 March 2022 in Dana Point,California,USA.

TheRothpresentationrecordingisaccessiblenowontheAlteritywebsiteunderNews.

AboutAlterityTherapeuticsLimited

AlterityTherapeuticsisaclinicalstagebiotechnologycompanydedicatedtocreatinganalternatefutureforpeoplelivingwithneurodegenerativediseases.TheCompany'sleadasset,ATH434,hasthe potential to treat various Parkinsonian disorders. Alterity also has a broad drug discoveryplatform generating patentable chemical compounds to intercede in disease processes. TheCompanyisbasedinMelbourne,Australia,andSanFrancisco,USA.Forfurtherinformationpleasevisitthe Company'swebsiteatwww.alteritytherapeutics.com.

Authorisation&Additionalinformation

ThisannouncementwasauthorizedbyDavidStamler,CEOofAlterityTherapeuticsLimited.

View original content to download multimedia:https://www.prnewswire.com/news-releases/alterity-therapeutics-to-present-at-the-34th-annual-roth-conference-301496634.html